Skye Bioscience (SKYE) Total Debt (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Total Debt of $250338.0 for Q1 2026, down 86.91% year-over-year from $1.9 million in Q1 2025, and down 87.81% quarter-over-quarter from $2.1 million in Q3 2025.
Skye Bioscience (SKYE) Total Debt (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Total Debt for 10 consecutive years, with $250338.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt fell 86.91% year-over-year to $250338.0; the TTM figure through Mar 2026 stood at $250338.0 (down 86.91% YoY), while the FY2024 annual figure was $1.8 million, down 79.2% from the prior year.
- Total Debt fell to $250338.0 in Q1 2026 per SKYE's latest filing, from $2.1 million in the prior quarter.
- Across five years, Total Debt topped out at $8.7 million in Q4 2023 and bottomed at $250338.0 in Q1 2026.
- Historically, Total Debt has averaged $3.6 million across 5 years, with a median of $2.1 million in 2022.
- Annual changes were most pronounced in 2022 — Total Debt jumped 1724.97% — and 2026, when it tumbled 86.91%.
- Skye Bioscience's Total Debt stood at $8.1 million in 2022, then increased by 8.57% to $8.7 million in 2023, then plunged by 79.2% to $1.8 million in 2024, then rose by 12.95% to $2.1 million in 2025, then tumbled by 87.81% to $250338.0 in 2026.
- Business Quant data shows SKYE's Total Debt at $250338.0 in Q1 2026, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 9.34 Bn |
| 10 | Skye Bioscience | 10.62 Mn | 10.62 Mn | - | 5.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 250,338.00 |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 8.74 Mn |
| Sep 30, 2023 | 6.21 Mn |
| Mar 31, 2023 | 6.21 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | 480,615.00 |
| Jun 30, 2022 | 572,461.00 |
| Mar 31, 2022 | 2.13 Mn |
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | 450,000.00 |
| Mar 31, 2021 | 116,700.00 |
| Dec 31, 2020 | 116,700.00 |
| Sep 30, 2020 | 116,700.00 |
| Jun 30, 2020 | 116,700.00 |